Drug Information
Drug Generic Name | RITUXIMAB |
Drug Class | ALKYLATING AGENTS |
Chapter | Malignant Disease & Immunosuppression |
This is a monoclonal antibody which causes lysis of B lymphocytes Indications: Chemotherapy resistant advanced follicular lymphoma of stage III or IV; diffuse large B- cell non – Hodgkins lymphoma in combination with other chemotherapy; advanced follicular lymphoma with other chemotherapeutic agents. Cautions: In patients receiving cardiotoxic chemotherapy or history of cardiovascular disease because exacerbation of angina, arrhythmia, heart failure has been reported. Contra-indications: breast feeding Side effect: Infusion-related side effects (including cytokine release syndrome) like chills, fever, nausea, vomiting, hypersensitivity reactions such as anaphylaxis, urticaria, bronchospasm, dyspnea and angioedema, flushing & tumour pain; Severe cytokine release syndrome (characterized by severe dyspnea) and associated with features of tumour lysis syndrome have occurred 1-2 hours after infusion. Dose: 375mg/meter squared once a week for 4 infusions if given as monotherapy and 8 if given with chemotherapy. |
|
Brand Name |
|